Effectiveness and durability of the mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy

Competing Interest Statement

J.B. is a part-time employee and a minority shareholder of Sotio, a.s. P.P. is a member of the advisory board of the GSK and received a consultancy fee from AstraZeneca, Novartis, Chiesi and speakers fee from GSK and Novartis. M.P., P.T., D.S., M.R, J.L., A.V., and Da.S. declare no conflicts of interest.

Funding Statement

Research in the authors' laboratories was supported by the institutional IPE2 funding of the Charles University, Second Faculty of Medicine in Prague.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee/IRB of the Motol University Hospital in Prague gave ethical approval for this work. The protocol approval number is EK-346/21.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes